查尔斯河实验室公司(CRL)股价在盘前大涨14.48%,主要由于公司上调了2024年全年利润预期。
该公司此前公布的第三季度业绩超过了分析师预期。公司上调全年利润预期的主要原因是,生物技术客户对其药物发现和开发服务的需求趋于稳定。自去年以来,合同研究机构的生物技术客户一直在减少支出,但最近的降息可能会改善生物技术公司的融资环境,从而提振对查尔斯河的服务需求。
公司CEO詹姆斯·福斯特表示,小型生物技术公司2024年的资金状况有所改善,公司服务的订单和取消订单情况也出现了稳定的早期迹象。此外,大型制药商的总体需求趋势似乎没有进一步恶化。所有这些因素共同推动了公司上调全年利润预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.